A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation (NCT03647917) | Clinical Trial Compass
CompletedEarly Phase 1
A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation
United States12 participantsStarted 2019-06-18
Plain-language summary
The overall goal of this study is to develop regenerative cell therapy for use in female patients with aging skin. The primary objective of this proposal is to conduct a pilot study on the efficacy and safety of using PRP to treat this condition in females.
Who can participate
Age range45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Only female patients are eligible
ā. Patients must be 45 years of age or older
ā. Patients must have signs of skin aging on face (wrinkles, rough texture, skin atrophy and skin laxity) and hands (loss of fat tissue and visibility of veins and tendons).
ā. Patients must have been on stable birth control for the past 6 months if able to conceive
ā. Patients are able and willing to provide written informed consent after the study is fully explained
Exclusion criteria
ā. Patients with clinically abnormal platelet count, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator
ā. Patients who have had any cosmetic procedures meant to address skin aging of face and hands 3 months prior to enrollment
ā. Patients who have had resurfacing laser on face or hands within one year prior to enrollment
ā. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry
ā. Patients who are pregnant or currently breast-feeding
ā. Patients with systemic, rheumatic, or inflammatory disease or who are immunosuppressed
ā. Patients with ongoing infectious disease, including HIV and hepatitis